Related references
Note: Only part of the references are listed.Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism
K. A. Blum et al.
ANNALS OF ONCOLOGY (2010)
High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints
R. GERLI et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Nicole M. Okeley et al.
CLINICAL CANCER RESEARCH (2010)
CD30 Ligand/CD30 Plays a Critical Role in Th17 Differentiation in Mice
Xun Sun et al.
JOURNAL OF IMMUNOLOGY (2010)
CD30 Ligand Is a Target for a Novel Biological Therapy against Colitis Associated with Th17 Responses
Xun Sun et al.
JOURNAL OF IMMUNOLOGY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Andres Forero-Torres et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders
Madeleine Duvic et al.
CLINICAL CANCER RESEARCH (2009)
Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
Andreas Engert et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
Massimo Federico et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The Survival of Memory CD4+ T Cells within the Gut Lamina Propria Requires OX40 and CD30 Signals
David R. Withers et al.
JOURNAL OF IMMUNOLOGY (2009)
Standard therapy of advanced Hodgkin lymphoma
J. Kuruvilla
Hematology-American Society of Hematology Education Program (2009)
Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials
M. Sieniawski et al.
ANNALS OF ONCOLOGY (2008)
Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
Ezogelin Oflazoglu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice
Xun Sun et al.
GASTROENTEROLOGY (2008)
A Novel Role of CD30L/CD30 Signaling by T-T Cell Interaction in Th1 Response against Mycobacterial Infection
Ce Tang et al.
JOURNAL OF IMMUNOLOGY (2008)
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
Nancy L. Bartlett et al.
BLOOD (2008)
CD30 supports lung inflammation
Sang-Yun Nam et al.
INTERNATIONAL IMMUNOLOGY (2008)
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
Ezogelin Oflazoglu et al.
BLOOD (2007)
TNF family ligands define niches for T cell memory
Laurent Sabbagh et al.
TRENDS IN IMMUNOLOGY (2007)
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma
Stephen M. Ansell et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis
Carlo Visco et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Expression of CD30 (Ber-H2) in nasopharyngeal carcinoma, undifferentiated type and lymphoepithelioma-like carcinoma. A comparison study with anaplastic large cell lymphoma
J. R. Kneile et al.
HISTOPATHOLOGY (2006)
Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin's lymphoma study group
K Behringer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A novel role of CD30/CD30 ligand signaling in the generation of long-lived memory CD8+ T cells
H Nishimura et al.
JOURNAL OF IMMUNOLOGY (2005)
The fully human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib-induced apoptosis
B Böll et al.
BLOOD (2005)
Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics
CG Cerveny et al.
LEUKEMIA (2005)
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody
R Schnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory
FMC Gaspal et al.
JOURNAL OF IMMUNOLOGY (2005)
Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease
I Aurer et al.
ONKOLOGIE (2005)
c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis
S Mathas et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma
H Venkatesh et al.
CLINICAL LYMPHOMA (2004)
CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease
BR Blazar et al.
JOURNAL OF IMMUNOLOGY (2004)
Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines
F Heuck et al.
JOURNAL OF IMMUNOTHERAPY (2004)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma
P Borchmann et al.
BLOOD (2003)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells
H Kashkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
V Diehl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma
R Schnell et al.
ANNALS OF ONCOLOGY (2003)
Hodgkin and Reed-Stemberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints:: analyses using tissue microarrays
JF García et al.
BLOOD (2003)
Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma
R Zanotti et al.
ANNALS OF ONCOLOGY (2002)
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma
P Borchmann et al.
BLOOD (2002)
TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism
H Harlin et al.
JOURNAL OF IMMUNOLOGY (2002)
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial
N Schmitz et al.
LANCET (2002)
Long-term follow-up of Hodgkin's disease trial
GP Canellos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Suppression of an IL-13 autocrine growth loop in a human Hodgkin/Reed-Sternberg tumor cell line by a novel IL-13 antagonist
Y Oshima et al.
CELLULAR IMMUNOLOGY (2001)
Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells
K Sundarapandiyan et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway
M Terabe et al.
NATURE IMMUNOLOGY (2000)
CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis
H Muta et al.
JOURNAL OF IMMUNOLOGY (2000)
Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: Distinction between Hodgkin's disease and anaplastic large cell lymphoma
PL Hsu et al.
LABORATORY INVESTIGATION (2000)